SK Bioscience Co Ltd (302440) - Total Liabilities

Latest as of September 2025: ₩847.96 Billion KRW ≈ $574.65 Million USD

Based on the latest financial reports, SK Bioscience Co Ltd (302440) has total liabilities worth ₩847.96 Billion KRW (≈ $574.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 302440 cash flow conversion to assess how effectively this company generates cash.

SK Bioscience Co Ltd - Total Liabilities Trend (2018–2024)

This chart illustrates how SK Bioscience Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check SK Bioscience Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

SK Bioscience Co Ltd Competitors by Total Liabilities

The table below lists competitors of SK Bioscience Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Société BIC SA PA:BB	France	€1.06 Billion
Hanesbrands Inc NYSE:HBI	USA	$3.83 Billion
Azelis Group NV BR:AZE	Belgium	€2.69 Billion
Ecopro Co. Ltd KQ:086520	Korea	₩5.29 Trillion
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	China	CN¥1.04 Billion
Guangdong Advertising Co Ltd SHE:002400	China	CN¥6.04 Billion
Beijing TRS Information Tech SHE:300229	China	CN¥331.01 Million
ISC Co. Ltd KQ:095340	Korea	₩78.49 Billion

Liability Composition Analysis (2018–2024)

This chart breaks down SK Bioscience Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 302440 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.27	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SK Bioscience Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SK Bioscience Co Ltd (2018–2024)

The table below shows the annual total liabilities of SK Bioscience Co Ltd from 2018 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩821.14 Billion ≈ $556.48 Million	+452.65%
2023-12-31	₩148.58 Billion ≈ $100.69 Million	-62.88%
2022-12-31	₩400.23 Billion ≈ $271.23 Million	-21.34%
2021-12-31	₩508.81 Billion ≈ $344.81 Million	+70.49%
2020-12-31	₩298.44 Billion ≈ $202.25 Million	+74.28%
2019-12-31	₩171.25 Billion ≈ $116.05 Million	-10.80%
2018-12-31	₩191.98 Billion ≈ $130.10 Million	--

About SK Bioscience Co Ltd

KO:302440 Korea Biotechnology

Market Cap

$2.29 Billion

₩3.38 Trillion KRW

Market Cap Rank

#5783 Global

#150 in Korea

Share Price

₩43050.00

Change (1 day)

-1.37%

52-Week Range

₩38800.00 - ₩60100.00

All Time High

₩335500.00